Lercanidipine hydrochloride oral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of lercanidipine hydrochloride.
Treatment of mild to moderate essential hypertension
Initially 10mg orally once daily, at least 15 minutes before a meal.
Dosage may be increased to 20mg according to patient response.
Titration should be gradual as it may take about 2 weeks to achieve maximal response.
Doses above 20 to 30mg daily are unlikely to increase antihypertensive effect, and side effects may be increased.
Patients with Renal Impairment
Mild to moderate renal impairment
Although the recommended dose may be tolerated in these patients care should be shown when approaching a 20mg daily dose.
Patients with Hepatic Impairment
Mild to moderate hepatic impairment
Although the recommended dose may be tolerated in these patients, an increase to 20mg daily must be used with caution.
Children under 18 years
Left ventricular outflow obstruction
Renal impairment - glomerular filtration rate below 30ml/minute
Severe hepatic impairment
Uncontrolled congestive cardiac failure
Within 1 month of a myocardial infarction
Precautions and Warnings
Glucose-galactose malabsorption syndrome
Ischaemic heart disease
Non-paced sinus node dysfunction
Reduced left ventricular function
Advise ability to drive/operate machinery may be affected by side effects
Advise patient to moderate alcohol intake during treatment
Advise patient to avoid grapefruit products
Female: Ensure adequate contraception during treatment
Very rarely patients with pre-existing angina pectoris may experience increased frequency, duration or severity of attacks.
Lercanidipine is associated with cloudy peritoneal effluent in patients on peritoneal dialysis. Cloudy peritoneal effluent can be mistaken for infective peritonitis with unnecessary hospitalisation and empiric antibiotic administration.
Pregnancy and Lactation
Lercanidipine hydrochloride is contraindicated during pregnancy.
The manufacturer does not recommend using lercanidipine during pregnancy or in women of childbearing-potential not using contraception. At the time of writing there is limited published information regarding the use of lercanidipine hydrochloride during pregnancy. Potential risks are unknown.
Lercanidipine hydrochloride is contraindicated during breastfeeding.
Use of lercanidipine hydrochloride when breastfeeding is contraindicated by the manufacturer. The presence of lercanidipine hydrochloride in human breast milk and effects on exposed infants are unknown.
Aggravation of angina
Increases in serum transaminases (reversible)
Peritoneal cloudy effluent
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: November 2019
Summary of Product Characteristics: Zanidip 10mg tablets. Recordati Pharmaceuticals Ltd. Revised November 2018.
Summary of Product Characteristics: Zanidip 20mg tablets. Recordati Pharmaceuticals Ltd. Revised November 2018.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.